Targeting Atrial Fibrillation with Special Tech Device, Kardium Expands to U.S.

Last month, Vancouver-based Kardium earned approval from the U.S. Food and Drug Administration for its Globe Pulsed Field System, clearing the way for the Canadian company’s atrial fibrillation treatment technology to enter the American market.

“The FDA approval of the Globe System represents the most significant milestone in the life of Kardium,” chief executive officer Kevin Chaplin remarked at the time.

The approval followed Kardium’s US$250M financing round this summer, which built on a $143M raise in 2024 and US$115M in 2021.

This week, the B.C.-based medical device innovator announced the successful completion of commercial procedures using its integrated mapping and ablation system.

The inaugural procedures were performed in the U.S. by Dr. Devi Nair, Chief of Cardiac Electrophysiology and EP Research at St. Bernards Medical Center in Jonesboro, Arkansas.

“We are very excited to offer our patients access to this groundbreaking new technology,” commented Dr. Nair. “The Globe Pulsed Field System gives me greater confidence that each lesion is delivered safely and effectively, to support better outcomes for my patients while also simplifying the procedure.”

Combining high-density mapping and ablation into a single catheter enables the Globe System to deliver precise, targeted ablation using thermal contact assessment and tailored electrode selection, according to Dr. Nair.

These capabilities allow for single-shot pulmonary vein isolation and other customizable lesion sets, helping physicians as they strive for better outcomes for patients with atrial fibrillation, adds Chaplin.

“These first commercial procedures with the Globe System signal the beginning of a new era in AF treatment,” the Kardium CEO stated. “We are proud to partner with leading physicians like Dr. Nair to bring the Globe Pulsed Field System into clinical practice allowing us to deliver a more personalized treatment for atrial fibrillation to improve long-term outcomes for patients.”

Data from a PULSAR study of the Globe Pulsed Field System, presented at the 2025 Heart Rhythm Society annual meeting, showed 78% freedom from atrial arrhythmia at one year in patients.

Following successful first commercial procedures, Chaplin says that Kardium will continue to collaborate with electrophysiology centres to expand the commercial availability of the Globe Pulsed Field System across the United States.